ArticleiScience2025

Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM).

Halime Kalkavan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.